ATE210943T1 - Ophthalmologisches abgabesystem - Google Patents

Ophthalmologisches abgabesystem

Info

Publication number
ATE210943T1
ATE210943T1 AT95923983T AT95923983T ATE210943T1 AT E210943 T1 ATE210943 T1 AT E210943T1 AT 95923983 T AT95923983 T AT 95923983T AT 95923983 T AT95923983 T AT 95923983T AT E210943 T1 ATE210943 T1 AT E210943T1
Authority
AT
Austria
Prior art keywords
ophthalmological
delivery system
delivery
formulations
alginate
Prior art date
Application number
AT95923983T
Other languages
English (en)
Inventor
Smadar Cohen
Esther Lobel
Original Assignee
Teva Pharma
Univ Ben Gurion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Univ Ben Gurion filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE210943T1 publication Critical patent/ATE210943T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT95923983T 1994-06-20 1995-06-19 Ophthalmologisches abgabesystem ATE210943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26229494A 1994-06-20 1994-06-20
PCT/US1995/007789 WO1995035073A1 (en) 1994-06-20 1995-06-19 Ophthalmic delivery system

Publications (1)

Publication Number Publication Date
ATE210943T1 true ATE210943T1 (de) 2002-01-15

Family

ID=22996942

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95923983T ATE210943T1 (de) 1994-06-20 1995-06-19 Ophthalmologisches abgabesystem

Country Status (6)

Country Link
US (1) US5776445A (de)
EP (1) EP0777451B1 (de)
AT (1) ATE210943T1 (de)
DE (1) DE69524772D1 (de)
IL (1) IL114193A (de)
WO (1) WO1995035073A1 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106819A (en) * 1996-12-31 2000-08-22 Sucher; David F. Methods of treating headache and functional extraocular and intraocular myotendinitis
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
FR2777189B1 (fr) * 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
FR2779953B1 (fr) * 1998-06-22 2000-08-11 Codif International Sa Procede d'elaboration d'un produit cosmetique destine a proteger la peau contre les agressions resultant de la pollution de l'air ambiant
US6730691B1 (en) * 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) * 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1476135A1 (de) * 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmische formulierung mit gummi-system
SI1534286T1 (sl) 2002-07-29 2010-04-30 Rigel Pharmaceuticals Inc Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
MXPA05011896A (es) * 2003-05-05 2006-05-25 Univ Ben Gurion Preparaciones polimericas reticuladas inyectables y sus usos.
EP1663242B1 (de) 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
US20090169520A1 (en) * 2004-01-09 2009-07-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation
CN1921833A (zh) * 2004-02-26 2007-02-28 博士伦公司 藻酸盐粘弹性组合物、使用方法及包装
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US20070004672A1 (en) * 2005-07-01 2007-01-04 Dharmendra Jani Long lasting alginate dry eye, related methods of manufacture and methods of use
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
ES2380551T3 (es) 2006-11-21 2012-05-16 Rigel Pharmaceuticals, Inc. Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
US20080153908A1 (en) * 2006-12-20 2008-06-26 Jani Dharmendra M Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition
WO2008088612A1 (en) * 2006-12-20 2008-07-24 Bausch & Lomb Incorporated Method of stimulating the production of mucin in the eye of a patient
US7659259B2 (en) * 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
WO2008082948A2 (en) * 2006-12-29 2008-07-10 Bausch & Lomb Incorporated Ophthalmic alginate composition related methods of manufacture and methods of use
CN101674807B (zh) * 2007-05-04 2013-03-20 博士伦公司 用于缓解、改善、治疗或预防干眼症的组合物及其制备和使用方法
KR20100016285A (ko) * 2007-05-07 2010-02-12 보오슈 앤드 롬 인코포레이팃드 안구건조 상태를 감소, 개선, 치료 또는 예방하기 위한 조성물 및 이의 제조 및 사용 방법
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US9096819B2 (en) 2008-01-31 2015-08-04 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer
US20110046033A1 (en) 2008-01-31 2011-02-24 Jinzhong Zhang Multipurpose Lens Care Solution with Benefits to Corneal Epithelial Barrier Function
US9481856B2 (en) * 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
KR20110042282A (ko) * 2008-06-12 2011-04-26 노파르티스 아게 눈 전면에 대한 지속 전달제로서의 인 시츄 겔화 시스템
EP2346513A1 (de) * 2008-09-15 2011-07-27 Bausch & Lomb Incorporated Zusammensetzungen mit polymeren mit aminozuckereinheiten und verfahren zu ihrer herstellung und verwendung
US20100087550A1 (en) 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
JP5815411B2 (ja) 2008-12-30 2015-11-17 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジンジアミンキナーゼ阻害剤
PL2389372T3 (pl) 2009-01-23 2016-02-29 Rigel Pharmaceuticals Inc Kompozycje i sposoby hamowania szlaku JAK
EP3620154A1 (de) 2009-02-06 2020-03-11 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
CA2768543C (en) 2009-07-28 2017-06-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
CA2828833C (en) 2010-03-03 2020-11-03 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
AU2011242562B2 (en) 2010-04-24 2016-10-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR101937495B1 (ko) 2010-07-28 2019-01-10 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
ES2600928T3 (es) 2010-08-27 2017-02-13 Neonc Technologies Inc. Composiciones farmacéuticas que comprenden derivados de alcohol perilílico
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20180039185A (ko) 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
EA201390876A1 (ru) 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CA2828360A1 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
EP3682896A1 (de) 2011-04-28 2020-07-22 University of Southern California Aus menschlichen myeloiden suppressorzellen gewonnene krebsmarker
US8809378B2 (en) 2011-06-19 2014-08-19 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN105884743B (zh) 2011-06-19 2019-08-06 威尔金制药(Nc)有限公司 金属酶抑制剂化合物
EA201490052A1 (ru) 2011-06-23 2014-04-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
EP3351541A1 (de) 2011-12-11 2018-07-25 Viamet Pharmaceuticals (NC), Inc. Metalloenzyminhibitorverbindungen
EA026209B1 (ru) 2012-01-20 2017-03-31 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
NZ629898A (en) 2012-03-23 2016-04-29 Oxigene Inc Compositions and methods for inhibition of cathepsins
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
BR112015031253B1 (pt) 2013-06-13 2021-09-28 Orgenesis Ltd. Método para produção de uma população de células transdiferenciada
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3872069A1 (de) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmazeutische zusammensetzungen mit perillylalkoholderivaten
EP4279064A3 (de) 2015-05-12 2024-02-28 Incept, LLC Arzneimittelabgabe aus hydrogelen
ES2811136T3 (es) 2015-08-04 2021-03-10 Rigel Pharmaceuticals Inc Compuestos de benzazol y métodos para obtener y usar los compuestos
WO2017117393A1 (en) 2015-12-30 2017-07-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP3475263B1 (de) 2016-06-27 2022-12-28 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidinverbindungen und dessen verwendung als irak4 hemmer
ES2939232T3 (es) 2016-10-26 2023-04-20 Rigel Pharmaceuticals Inc Derivados de oxazol para uso como inhibidores de IRAK y método para su preparación
ES2946001T3 (es) 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
EP3562487B1 (de) 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzym-inhibitor-verbindungen
EP3562306B1 (de) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzym-inhibitor-verbindungen
WO2018207179A1 (en) 2017-05-08 2018-11-15 Orgenesis Ltd. Transdifferentiated cell populations and methods of use thereof
CN111032642B (zh) 2017-06-29 2023-07-18 里格尔药品股份有限公司 激酶抑制剂及制造和使用方法
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
BR112020016074A2 (pt) 2018-02-08 2020-12-08 Neonc Technologies, Inc Métodos de permeabilização da barreira hematoencefálica
PT3788044T (pt) 2018-05-03 2023-08-31 Rigel Pharmaceuticals Inc Compostos inibidores de rip1 e métodos para preparar e usar os mesmos
KR102823195B1 (ko) 2018-05-03 2025-06-20 리겔 파마슈티칼스, 인크. Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
CN114269383A (zh) 2019-01-08 2022-04-01 菲斯生物制药公司 金属酶抑制剂化合物
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
PH12022550466A1 (en) 2019-08-30 2023-03-06 Rigel Pharmaceuticals Inc Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
EP4025574B1 (de) 2019-09-06 2025-05-07 Rigel Pharmaceuticals, Inc. Rip1-inhibitorverbindungen und verfahren zu ihrer herstellung und verwendung
CN115298184B (zh) 2019-11-07 2025-01-28 里格尔药品股份有限公司 杂环rip1抑制化合物
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
US12384775B2 (en) 2022-03-23 2025-08-12 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3601132A1 (de) * 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
IT1203814B (it) * 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
JP2668730B2 (ja) * 1988-03-09 1997-10-27 雪印乳業株式会社 天然ポリマーを用いた徐放性製剤
FR2645439B1 (fr) * 1989-04-07 1991-06-21 Oreal Procede de preparation de capsules d'alginate(s) particulierement adaptees a un usage cosmetique, appareil pour sa mise en oeuvre et composition cosmetique contenant lesdites capsules
NO171069C (no) * 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物

Also Published As

Publication number Publication date
DE69524772D1 (de) 2002-01-31
EP0777451A1 (de) 1997-06-11
EP0777451A4 (de) 1998-06-10
EP0777451B1 (de) 2001-12-19
IL114193A0 (en) 1995-10-31
IL114193A (en) 2000-02-29
WO1995035073A1 (en) 1995-12-28
US5776445A (en) 1998-07-07

Similar Documents

Publication Publication Date Title
DE69524772D1 (de) Ophthalmologisches abgabesystem
BR0014203A (pt) Formulações de suspensão tópicas contendo ciprofloxacina e dexametasona
AU6185398A (en) Charged lipids and uses for the same
DK0928206T3 (da) Hydrokolloid sårgel
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
EP0783299A4 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
EP0693281A3 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
DK0759687T3 (da) Anvendelse af gelpræparater som bejdsemidler
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
ATE284996T1 (de) Papiertuch enthaltend antivirale wirkstoffe die hautfreundlich sind
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
TW327602B (en) A pharmaceutical composition of an ophthalmic suspension containing difluprednate
AR004168A1 (es) Composicion farmaceutica liquida vertible acuosa
DE60002719D1 (de) Ophthalmische zusammensetzungen in form wässriger gele
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
MY103079A (en) New ophtalmological composition of matter
SE9403905D0 (sv) New formulations
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
SE9302203D0 (sv) Composition for ophthalmic use
KR950700685A (ko) 최음제로서 사용되는 요드화수소산(use of hydriodic acid as an aphrodisiac)
ES512751A0 (es) "procedimiento para la preparacion de un colirio antiseptico para afecciones oculares".
ES2132642T3 (es) Concentrados acuosos para suspension de endosulfan.
RU94036667A (ru) Биоэнергомодулятор

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties